Yair Herishanu

4.1k total citations
87 papers, 1.2k citations indexed

About

Yair Herishanu is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Yair Herishanu has authored 87 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Genetics, 48 papers in Pathology and Forensic Medicine and 24 papers in Oncology. Recurrent topics in Yair Herishanu's work include Chronic Lymphocytic Leukemia Research (52 papers), Lymphoma Diagnosis and Treatment (45 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). Yair Herishanu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (52 papers), Lymphoma Diagnosis and Treatment (45 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). Yair Herishanu collaborates with scholars based in Israel, United States and Canada. Yair Herishanu's co-authors include Ben‐Zion Katz, Aaron Polliack, Chava Perry, Lev Shvidel, Irit Avivi, Andrew Lipsky, Elizabeth Naparstek, Adrian Wiestner, Sigi Kay and Ur Metser and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Yair Herishanu

85 papers receiving 1.1k citations

Peers

Countries citing papers authored by Yair Herishanu

Since Specialization

Citations

This map shows the geographic impact of Yair Herishanu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yair Herishanu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yair Herishanu more than expected).

Fields of papers citing papers by Yair Herishanu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yair Herishanu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yair Herishanu. The network helps show where Yair Herishanu may publish in the future.

Co-authorship network of co-authors of Yair Herishanu

This figure shows the co-authorship network connecting the top 25 collaborators of Yair Herishanu. A scholar is included among the top collaborators of Yair Herishanu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yair Herishanu. Yair Herishanu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study 2023 ·European Journal Of Haematology ·Ofrat Beyar‐Katz, Chava Perry, (unknown), (unknown), Efrat Luttwak, Batia Avni, Tsila Zuckerman, (unknown), Polina Stepensky, (unknown), Yael Bar‐On, Diana Libster, (unknown), Odelia Amit, Uri Greenbaum, (unknown), Yair Herishanu, Noam Benyamini, Irit Avivi, Ron Ram	4
2	Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study 2023 ·Blood ·Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vučinić, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, (unknown), Patricia Marinello, John M. Timmerman	3
3	Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge 2023 ·British Journal of Haematology ·Yotam Bronstein, Shai Levi, Yair Herishanu	3
4	Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis 2022 ·European Journal of Cancer ·(unknown), Ainsley Ryan Yan Bin Lee, (unknown), Lauren Shapiro, Astha Thakkar, Balázs Halmos, Albert Grinshpun, Yair Herishanu, Ohad Benjamini, Tamar Tadmor, Rachna T. Shroff, Bonnie LaFleur, Deepta Bhattacharya, (unknown), Jeremy Tey, Soo Chin Lee, Louis Yi Ann Chai, Yu Yang Soon, Raghav Sundar, (unknown)	26
5	Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma? 2022 ·Cancers ·Dan Cohen, Chava Perry, (unknown), (unknown), Yair Herishanu, Efrat Luttwak, Einat Even‐Sapir, Irit Avivi	7
6	The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients 2022 ·Clinical Microbiology and Infection ·Esther Saiag, Ayelet Grupper, Irit Avivi, Ori Elkayam, Ron Ram, Yair Herishanu, Yaël C. Cohen, Chava Perry, Victoria Furer, Helena Katchman, Liane Rabinowich, Merav Ben‐Yehoyada, Tami Halperin, Roni Baruch, Hanoch Goldshmidt, David Hagin, Ronen Ben‐Ami, Eli Sprecher, David Bomze	15
7	Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma 2021 ·British Journal of Haematology ·Irit Avivi, (unknown), (unknown), (unknown), M. Morales, Anat Aharon, (unknown), Svetlana Trestman, Chava Perry, Noam Benyamini, Moshe Mittelman, Yaara Tabib, (unknown), (unknown), Yair Herishanu, Efrat Luttwak, Yaël C. Cohen	50
8	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy 2021 ·European Journal of Nuclear Medicine and Molecular Imaging ·Dan Cohen, (unknown), Yaël C. Cohen, Chava Perry, Irit Avivi, Yair Herishanu, Einat Even‐Sapir	35
9	Outcomes of second‐line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials 2018 ·European Journal Of Haematology ·Erel Joffe, Neta Goldschmidt, Osnat Bairey, Riva Fineman, Rosa Ruchlemer, Naomi Rahimi‐Levene, Lev Shvidel, Uri Greenbaum, Ariel Aviv, Tamar Tadmor, (unknown), Ariela Arad, Aaron Polliack, Yair Herishanu, (unknown)	5
10	Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma 2017 ·Bone Marrow Transplantation ·Erel Joffe, Dana Rosenberg, Uri Rozovski, Chava Perry, Ilya Kirgner, Svetlana Trestman, (unknown), (unknown), Nadav Sarid, (unknown), (unknown), Yair Herishanu, Elizabeth Naparstek	9
11	Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival 2017 ·Hematological Oncology ·Erel Joffe, (unknown), Osnat Bairey, Riva Fineman, Rosa Ruchlemer, Naomi Rahimi‐Levene, Lev Shvidel, Uri Greenbaum, Ariel Aviv, Tamar Tadmor, Andrei Braester, Neta Goldschmidt, Aaron Polliack, Yair Herishanu	3
12	Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study 2017 ·Blood ·(unknown), Yair Herishanu, Nadav Sarid, (unknown), Irit Avivi, Lev Shvidel, Osnat Bairey, Noa Lavi, Netanel A. Horowitz, Abraham Avigdor, Neta Goldschmidt, (unknown), (unknown)	1
13	Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma 2015 ·Leukemia & lymphoma ·Nadav Sarid, Erel Joffe, (unknown), Irit Avivi, Aaron Polliack, (unknown), Yair Herishanu	7
14	Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis 2013 ·Cancer ·Tamar Tadmor, Lev Shvidel, Ariel Aviv, Rosa Ruchlemer, Osnat Bairey, (unknown), Yair Herishanu, (unknown), (unknown), (unknown), Jonathan Ben‐Ezra, Jacob Bejar, Aaron Polliack, (unknown)	11
15	Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond 2013 ·Leukemia & lymphoma ·Ben‐Zion Katz, Yair Herishanu	38
16	Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival 2013 ·Leukemia Research ·Yair Herishanu, Sigi Kay, Nadav Sarid, (unknown), Rony Braunstein, (unknown), Varda Deutsch, Jonathan Ben‐Ezra, Elizabeth Naparstek, Chava Perry, Ben‐Zion Katz	17
17	Early‐mid treatment C‐reactive protein level is a prognostic factor in aggressive non‐Hodgkin’s lymphoma 2007 ·European Journal Of Haematology ·Yair Herishanu, (unknown), Rony Braunstein, Ur Metser, (unknown), Ori Rogowski, Shlomo Berliner, Aaron Polliack, Elizabeth Naparstek	20
18	Fatal Interstitial Pneumonitis Related to Rituximab-Containing Regimen 2006 ·Clinical Lymphoma & Myeloma ·Yair Herishanu, Aaron Polliack, Leonor Leider–Trejo, (unknown), Ur Metser, Elizabeth Naparstek	27
19	Chronic lymphocytic leukemia: A review of some new aspects of the biology, factors influencing prognosis and therapeutic options 2005 ·Transfusion and Apheresis Science ·Yair Herishanu, Aaron Polliack	11
20	The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine 2002 ·Anti-Cancer Drugs ·Yair Herishanu, Michael Lishner, Yona Kitay‐Cohen	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact